{"id":"adjuvant-nivolumab-and-ipilimumab","safety":{"commonSideEffects":[{"rate":"30–40%","effect":"Fatigue"},{"rate":"25–35%","effect":"Diarrhea"},{"rate":"20–30%","effect":"Nausea"},{"rate":"20–25%","effect":"Rash"},{"rate":"5–10%","effect":"Immune-mediated colitis"},{"rate":"3–5%","effect":"Immune-mediated hepatitis"},{"rate":"2–5%","effect":"Immune-mediated pneumonitis"},{"rate":"5–10%","effect":"Immune-mediated endocrinopathy"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:00:34.049720","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, preventing immune evasion. Ipilimumab is a CTLA-4 inhibitor that enhances T-cell priming and activation. Combined, they provide dual checkpoint inhibition to maximize anti-tumor immunity in the adjuvant (post-surgical) setting to reduce recurrence risk.","oneSentence":"Nivolumab and ipilimumab together block immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor T-cell responses in adjuvant settings.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:53.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of melanoma (resected stage III/IV)"},{"name":"Adjuvant treatment of renal cell carcinoma (resected stage III/IV)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT04817254","phase":"PHASE2","title":"Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Glioblastoma, Gliosarcoma, Malignant Glioma","enrollment":47},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT07230613","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy in Patients With Localized Melanoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-12","conditions":"Cutaneous Melanoma, Stage III, Mucosal Melanoma","enrollment":50},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT02656706","phase":"PHASE2","title":"Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brown University","startDate":"2016-07","conditions":"Melanoma","enrollment":22},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT05254184","phase":"PHASE1","title":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-01","conditions":"Non-Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT04013854","phase":"PHASE2","title":"Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-01-01","conditions":"Melanoma Stage III, Melanoma","enrollment":67},{"nctId":"NCT05704933","phase":"EARLY_PHASE1","title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-06-06","conditions":"Metastatic Melanoma, Metastasis to Brain","enrollment":1},{"nctId":"NCT04620200","phase":"PHASE2","title":"Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-08-11","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT02990611","phase":"","title":"Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-12-06","conditions":"Melanoma","enrollment":1087},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT04006262","phase":"PHASE2","title":"Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-10-23","conditions":"Localized Oesogastric Adenocarcimona, MSI and or dMMR","enrollment":32},{"nctId":"NCT03406247","phase":"PHASE2","title":"Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-02-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":140},{"nctId":"NCT02388906","phase":"PHASE3","title":"Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03-16","conditions":"Melanoma","enrollment":906},{"nctId":"NCT02196961","phase":"PHASE2","title":"Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","startDate":"2014-06","conditions":"Merkel Cell Carcinoma","enrollment":180},{"nctId":"NCT04133948","phase":"PHASE1, PHASE2","title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-01-07","conditions":"Malignant Melanoma Stage III","enrollment":44},{"nctId":"NCT03387761","phase":"PHASE1","title":"Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-01-15","conditions":"Urothelial Carcinoma","enrollment":54},{"nctId":"NCT03138161","phase":"PHASE1, PHASE2","title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2017-04-13","conditions":"Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma","enrollment":250},{"nctId":"NCT06097975","phase":"PHASE1","title":"A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2024-03-15","conditions":"Recurrent Glioblastoma","enrollment":18},{"nctId":"NCT04382664","phase":"PHASE2","title":"UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2020-05-27","conditions":"Malignant Melanoma","enrollment":156},{"nctId":"NCT03138512","phase":"PHASE3","title":"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-07","conditions":"Carcinoma, Renal Cell","enrollment":1641},{"nctId":"NCT04605146","phase":"NA","title":"Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-05-05","conditions":"Melanoma, Lung Cancer, Renal Cancer","enrollment":100},{"nctId":"NCT06566391","phase":"PHASE2","title":"Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2019-03-05","conditions":"Melanoma","enrollment":35},{"nctId":"NCT06163170","phase":"","title":"A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-14","conditions":"Melanoma","enrollment":100},{"nctId":"NCT03798639","phase":"PHASE1","title":"Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer","status":"COMPLETED","sponsor":"Claire Verschraegen","startDate":"2019-01-07","conditions":"Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8","enrollment":7},{"nctId":"NCT02519322","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-02-02","conditions":"Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma","enrollment":53},{"nctId":"NCT04949113","phase":"PHASE3","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2021-07-08","conditions":"Malignant Melanoma Stage III","enrollment":423},{"nctId":"NCT03443856","phase":"PHASE2","title":"Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-07-17","conditions":"Gastric and Esophagogastric Junction Adenocarcinoma","enrollment":197},{"nctId":"NCT02977052","phase":"PHASE2","title":"Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-11-24","conditions":"Malignant Melanoma Stage III","enrollment":186},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT03003637","phase":"PHASE1, PHASE2","title":"ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-02-28","conditions":"Immunotherapy, Head and Neck Neoplasms","enrollment":33},{"nctId":"NCT03700905","phase":"PHASE3","title":"Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy","status":"UNKNOWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-08-21","conditions":"Head and Neck Cancer","enrollment":276},{"nctId":"NCT03528408","phase":"PHASE2","title":"Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma","status":"UNKNOWN","sponsor":"Suthee Rapisuwon","startDate":"2018-07-26","conditions":"Melanoma, Ocular Melanoma","enrollment":52},{"nctId":"NCT05611229","phase":"","title":"Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-16","conditions":"Metastatic Melanoma","enrollment":1975},{"nctId":"NCT04107168","phase":"","title":"Microbiome Immunotherapy Toxicity and Response Evaluation","status":"UNKNOWN","sponsor":"CCTU- Cancer Theme","startDate":"2020-07-08","conditions":"Melanoma, Renal Cancer, Lung Cancer","enrollment":1800},{"nctId":"NCT05714371","phase":"","title":"Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-02","conditions":"Melanoma","enrollment":618},{"nctId":"NCT03241186","phase":"PHASE2","title":"Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Robert R. McWilliams, MD","startDate":"2017-09-12","conditions":"Mucosal Melanoma","enrollment":36},{"nctId":"NCT02449837","phase":"","title":"Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05","conditions":"Circulating Tumor Cells","enrollment":162},{"nctId":"NCT03526185","phase":"EARLY_PHASE1","title":"A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-02-06","conditions":"Metastatic Melanoma","enrollment":6},{"nctId":"NCT02437279","phase":"PHASE1","title":"Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-11-24","conditions":"Stage III Skin Melanoma","enrollment":20},{"nctId":"NCT03068455","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-04-11","conditions":"Melanoma","enrollment":1844},{"nctId":"NCT04495010","phase":"PHASE2","title":"Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-31","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03597282","phase":"PHASE1","title":"A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma","status":"TERMINATED","sponsor":"BioNTech US Inc.","startDate":"2018-10-08","conditions":"Metastatic Melanoma","enrollment":22},{"nctId":"NCT02941744","phase":"PHASE1, PHASE2","title":"A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-03","conditions":"Stage IIIC Skin Melanoma, Stage IV Skin Melanoma","enrollment":56},{"nctId":"NCT03220009","phase":"PHASE2","title":"Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-03","conditions":"Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvant Nivolumab and Ipilimumab","genericName":"Adjuvant Nivolumab and Ipilimumab","companyName":"Universitätsklinikum Hamburg-Eppendorf","companyId":"universit-tsklinikum-hamburg-eppendorf","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab and ipilimumab together block immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor T-cell responses in adjuvant settings. Used for Adjuvant treatment of melanoma (resected stage III/IV), Adjuvant treatment of renal cell carcinoma (resected stage III/IV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}